News

DUBLIN, Aug. 23, 2021 /PRNewswire/ — The “Global Anti-Obesity Drugs Market (2021-2026) by Drug Type, Drug Class, Medication, Distribution Channel, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering.

The Global Anti-Obesity Drugs Market is estimated to be USD 3.28 Bn in 2021 and is expected to reach USD 4.64 Bn by 2026, growing at a CAGR of 7.19%.Increased consumption of processed and unhealthy foods, lack of physical activity, lack of knowledge about the risk associated with obesity, and rising disposable money are some factors driving the demand for anti-obesity drugs.

Furthermost, the rising worry about being overweight or obese is exposing people to a greater risk of developing a variety of chronic illnesses, such as cardiovascular disease, cancer, and diabetes, etc., all of which have high treatment costs, so the public has become more conscious of obesity, which is prompting consumers to turn to anti-obesity medications.

In addition, the increasing healthcare spending, favorable reimbursement policies, substantial research and development efforts in the sector, and increased government and non-government organizations’ participation in raising awareness and funding research are expected to create more opportunities for the growth of this market.However, medication side effects, restricted availability of combination therapy, and growing acceptance of other options such as gyms, exercise spas, and other alternatives are likely to restrain and create a challenge for the global anti-obesity drugs market.

Some of the companies covered in this report are Alizyme, Arena Pharmaceuticals Inc, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Currax Pharmaceuticals LLC, etc. Market Segmentation

The Global Anti-Obesity Drugs Market is segmented further based on Drug Type, Drug Class, Medication, Distribution Channel, and Geography. By Drug Type, the market is classified as prescription drugs and OTC drugs. Amongst the two, the prescription drugs segment is estimated to hold the highest market share during the forecast period. By Drug Class, the market is classified as peripherally acting drugs and centrally acting drugs. Amongst the two, the peripherally acting drugs segment is estimated to hold the highest market share during the forecast period. By Medication, the market is classified as Monotherapies, Polytherapies, and others, others. Amongst all, the monotherapies segment is estimated to hold the highest market share during the forecast period. By Distribution Channel, the market is classified as hospital pharmacy, retail pharmacy, and online pharmacy. All the hospital pharmacy segment is estimated to hold the highest market share during the forecast period. Recent Developments

FDA accepts Eisai’s supplemental new drug application (SNDA) to update the labeling for anti-obesity agent Belviq. – 25th February 2019. CurraxT Pharmaceuticals LLC Announces the Acquisition of Nalpropion Pharmaceuticals, Inc. – 27th September 2019. Currax Launches Why Weight: Communicate Initiative to Encourage Conversations about Weight Loss- 25th June 2021 Key Topics Covered: 1 Report Description1.1 Study Objectives 1.2 Market Definition1.3 Currency1.4 Years Considered1.5 Language1.6 Key Shareholders 2 Research Methodology2.1 Research Process2.2 Data Collection and Validation2.3 Market Size Estimation2.4 Assumptions of the Study2.5 Limitations of the Study 3 Executive Summary3.1 Introduction3.2 Market Size and Segmentation3.3 Market Outlook 4 Market Influencers4.1 Drivers4.1.1 Increasing Consumption of Unhealthy food 4.1.2 Adoption of Unhealthy lifestyle4.2 Restraints4.2.1 Side Effect of Anti-Obesity Drug 4.3 Opportunities 4.3.1 Raising Public Awareness Towards a Healthy Lifestyle 4.4 Challenges4.4.1 Alternate Treatment Options Available4.4.2 Lack of Proper Awareness towards Weight Management 4.5 Trends 5 Market Analysis5.1 Regulatory Scenario5.2 Porter’s Five Forces Analysis5.3 Impact of COVID-195.4 Ansoff Matrix Analysis 6 Global Anti-Obesity Drugs Market, By Drug Type6.1 Introduction 6.2 Prescription Drugs6.3 OTC Drugs 7 Global Anti-Obesity Drugs Market, By Drug Class7.1 Introduction 7.2 Peripherally Acting Drugs7.3 Centrally Acting Drugs 8 Global Anti-Obesity Drugs Market, By Medication8.1 Introduction8.2 Monotherapies8.3 Polytherapies 8.4 Others 9 Global Anti-Obesity Drugs Market, By Distribution Channel9.1 Introduction9.2 Hospital Pharmacy 9.3 Retail Pharmacy9.4 Online Pharmacy 10 Global Anti-Obesity Drugs Market, By Geography 11 Competitive Landscape11.1 Competitive Quadrant11.2 Market Share Analysis11.3 Strategic Initiatives 12 Company Profiles

Alizyme Arena Pharmaceuticals Inc Bayer AG Boehringer Ingelheim GmbH Bristol- Myers Squibb Currax Pharmaceuticals LLC Eisai Co. Ltd F. Hoffmann-La Roche AG GlaxoSmithKline PLC Merck & Co. Inc Norgine BV, Novo Nordisk A Orexigen Therapeutics Pfizer Inc Rhythm Pharmaceuticals Shionogi Inc Sanofi Takeda Pharmaceuticals Vivus Inc Zydus Cadila For more information about this report visit https://www.researchandmarkets.com/r/yrctd1

Media Contact: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com      

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

View original content: https://www.prnewswire.com/news-releases/global-anti-obesity-drugs-markets-2021-2026-focus-on-peripherally–centrally-acting-drugs-monotherapies-polytherapies-301360509.html

SOURCE Research and Markets